Diovan Clears FDA For Post-Myocardial Infarction Mortality Reduction
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.
You may also be interested in...
Novartis’ Diovan Gets Pediatric Hypertension Nod
Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.
Novartis’ Diovan Gets Pediatric Hypertension Nod
Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.
Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth
Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.